New developments in the treatment of hepatitis C.
Rossi
S J
SJ
Gastroenterology Section and the Department of Medicine, Veterans Administration Medical Center, University of California, San Francisco 94121, USA.
Wright
T L
TL
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D012256:Riboflavin / Q000008:administration & dosage
D000998:Antiviral Agents; D004338:Drug Combinations; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012256:Riboflavin